ESTRO and ILROG define modern technical standards for total skin electron therapy
ESTRO consensus recommendations establish standardized dose, delivery, shielding and quality-assurance principles for total skin electron therapy.
ESTRO consensus recommendations establish standardized dose, delivery, shielding and quality-assurance principles for total skin electron therapy.
Accumulated gastrointestinal doses were generally lower than planned, while higher small-bowel dose showed exploratory associations with diarrhoea after MR-guided SABR.
Random forest reached external AUC 0.769 for 12-month radiation-induced hypothyroidism, but calibration and clinical utility weakened outside the development center.
Among 26 patients receiving whole-breast irradiation after perioperative brachytherapy, 5-year local-relapse-free survival was 100% with no grade ≥3 toxicity.
MRI radiomics predicted VEGFA expression with validation AUC 0.718, while high VEGFA independently correlated with worse overall survival.
SPC-guided planning reduced larynx and parotid doses without compromising target coverage in a 200-patient retrospective nasopharyngeal carcinoma series.
Metabolic syndrome affected 18.8% of Wilms tumor survivors versus 7.3% of matched controls, with abdominal radiotherapy emerging as an important risk factor.
Cardiovascular events occurred in 59% after definitive lung chemoradiotherapy, while higher heart V20 and V30 independently tracked with greater event risk.
Median online adaptive MR-guided treatment time fell 28% despite increasing complexity, with 78% of late-era fractions completed within 60 minutes.
Unplanned radiotherapy interruptions occurred in 35% and were associated with lower response, more toxicity and markedly worse six-month survival.
NRF2 directly activated WNT5A, sustaining β-catenin signaling, cancer stemness and radioresistance across esophageal cancer models.
Selective field-based imaging reduced mean setup time by about five minutes with similar geometric accuracy and dosimetric robustness.
Severe lymphopenia occurred in 44%, while baseline and week-2 lymphocyte counts outperformed 600 dosimetric variables for risk prediction.
Adding functional brain regions to CyberKnife optimization reduced dose to multiple structures by roughly 23%–39% while preserving target coverage.
Late urinary worsening occurred in 80% after >40 Gy prostate SBRT versus 68% after ≤40 Gy, while bowel outcomes remained similar.